基本信息
views: 251
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Also at Johns Hopkins, Dr. Hammers led the kidney cancer research efforts and played a major role in the development of immunotherapy with immune checkpoint inhibitors in kidney cancer. His work in immunotherapy has been nationally recognized, and he has been the principal investigator on several industry- and investigator-sponsored trials.
Dr. Hammers joined the UT Southwestern faculty in 2016. He is co-leader of clinical research and immunotherapy for the kidney cancer research program and will be continuing his research efforts to develop novel immunotherapies for kidney cancer.
Immunotherapy Expert
Dr. Hammers is an international thought leader in immunotherapy, a form of treatment that boosts the body’s own immune defenses to help fight cancer – and one that is changing the kidney cancer landscape.
His goal is to continue to develop and improve innovative immunotherapies for kidney cancer and provide access to them for UT Southwestern patients.
“Immunotherapy holds curative potential. It’s a real game changer in oncology, and UT Southwestern is helping to lead the way in the development of new treatments for kidney cancer patients,” Dr. Hammers says.
Dr. Hammers joined the UT Southwestern faculty in 2016. He is co-leader of clinical research and immunotherapy for the kidney cancer research program and will be continuing his research efforts to develop novel immunotherapies for kidney cancer.
Immunotherapy Expert
Dr. Hammers is an international thought leader in immunotherapy, a form of treatment that boosts the body’s own immune defenses to help fight cancer – and one that is changing the kidney cancer landscape.
His goal is to continue to develop and improve innovative immunotherapies for kidney cancer and provide access to them for UT Southwestern patients.
“Immunotherapy holds curative potential. It’s a real game changer in oncology, and UT Southwestern is helping to lead the way in the development of new treatments for kidney cancer patients,” Dr. Hammers says.
Research Interests
Papers共 253 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal for ImmunoTherapy of Cancerno. 4 (2024)
The New England journal of medicineno. 15 (2024): 1359-1371
The Journal of clinical investigationno. 14 (2024)
Journal for immunotherapy of cancerno. 4 (2024)
Judy S. Wang,Manish R. Sharma, William J. Edenfield,Kartik Sehgal,Do-Youn Oh, Yixing Jiang, Joel Michalski, Jeeyun Lee,Hans Hammers,Li-Yuan Bai,Chih-Hung Hsu, Brenda Dampier,
Cancer Researchno. 7_Supplement (2024)
Journal of Clinical Oncologyno. 6_suppl (2023): 604-604
crossref(2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn